CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.6B, above the global median of $1.18B
- PositionReturn on equity is -236.4%, lower than 95% of its Biotechnology peers (median -23.6%)
- Interpretations12 currently firing — 12
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
5.60BUSDvs all stocks (USD)
Revenue (TTM)
591.33MUSDvs all stocks (USD)
Profit Margin
-7.35%vs Biotechnology peers
Beta
1.06xvs all stocks
52-Week Change
155.95%vs all stocks
Market Capitalization
5.60BUSDvs all stocks (USD)
Enterprise Value
5.73BUSDvs all stocks (USD)
Forward P/E
10.48xvs Biotechnology peers
Price to Sales (TTM)
9.48xvs Biotechnology peers
Price to Book (MRQ)
55.66xvs Biotechnology peers
Enterprise to Revenue
9.69xvs Biotechnology peers
Gross Margin
94.55%vs Biotechnology peers
Profit Margin
-7.35%vs Biotechnology peers
Operating Margin
2.33%vs Biotechnology peers
Return on Assets (TTM)
-3.73%vs Biotechnology peers
Return on Equity (TTM)
-236.36%vs Biotechnology peers
Revenue (TTM)
591.33MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.48USDUpdated Sep 28, 2026Quarterly Revenue Growth
48.20%vs Biotechnology peers
Gross Profit (TTM)
350.12MUSDvs all stocks (USD)
EBITDA (TTM)
22.22MUSDvs all stocks (USD)
Net Income (TTM)
-67.68MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
48.17%vs Biotechnology peers
Operating Cash Flow (TTM)
92.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-18.25MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
490.73MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
10.34MUSDFY2025 · Dec 31, 2025Gross Profit
480.39MUSDFY2025 · Dec 31, 2025Operating Income
-62.82MUSDvs all stocks (USD)
Pre-tax Income
-49.27MUSDFY2025 · Dec 31, 2025Income Tax Expense
988.00KUSDFY2025 · Dec 31, 2025Net Income
-25.55MUSDFY2025 · Dec 31, 2025EBIT
-38.52MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
22.22MUSDFY2025 · Dec 31, 2025Research & Development
206.01MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
337.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.72MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
10.75MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.2900USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.2900USDFY2025 · Dec 31, 2025Basic Shares Outstanding
89.21MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
89.21MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-50.26MUSDFY2025 · Dec 31, 2025Operating Cash Flow
20.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
93.03MUSDFY2025 · Dec 31, 2025Interest Paid
8.84MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-50.26MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
60.74MUSDFY2025 · Dec 31, 2025Stock-based Compensation
44.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
183.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-26.97MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-85.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.12MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-58.16MUSDFY2025 · Dec 31, 2025Purchase of Investments
-237.14MUSDFY2025 · Dec 31, 2025Sale of Investments
323.60MUSDFY2025 · Dec 31, 2025Other Investing Activity
-404.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
86.05MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-68.90MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.10MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-71.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
94.17MSharesUpdated Sep 28, 2026Float Shares
93.22MSharesUpdated Sep 28, 2026Shares Short
12.96MSharesUpdated Sep 28, 2026Short Ratio
10.19daysvs all stocks
Short % of Shares Outstanding
17.90%vs all stocks
% Held by Insiders
0.69%vs all stocks
% Held by Institutions
115.01%vs all stocks
Total Cash (MRQ)
489.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.19USDUpdated Sep 28, 2026Total Debt (MRQ)
616.91MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
25.16xvs Biotechnology peers
Current Ratio (MRQ)
4.05xvs Biotechnology peers
Book Value per Share (MRQ)
1.07USDUpdated Sep 28, 2026Total Assets
604.44MUSDvs all stocks (USD)
Total Current Assets
437.56MUSDFY2025 · Dec 31, 2025Total Liabilities
490.36MUSDFY2025 · Dec 31, 2025Total Non-current Assets
166.87MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
330.46MUSDFY2025 · Dec 31, 2025Total Current Liabilities
159.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.03MUSDFY2025 · Dec 31, 2025Other Short-term Investments
229.76MUSDFY2025 · Dec 31, 2025Accounts Receivable
80.13MUSDFY2025 · Dec 31, 2025Inventory
5.88MUSDFY2025 · Dec 31, 2025Accounts Payable
24.80MUSDFY2025 · Dec 31, 2025Short-term Debt
5.88MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.19MUSDFY2025 · Dec 31, 2025Long-term Debt
322.86MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
7.60MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.47BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
114.83MUSDvs all stocks (USD)
52-Week Low
22.05USDUpdated Sep 28, 202652-Week High
68.73USDUpdated Sep 28, 202652-Week Change
155.95%vs all stocks
Beta
1.06xvs all stocks
50-Day MA
62.00USDUpdated Sep 28, 2026200-Day MA
44.39USDUpdated Sep 28, 2026Avg 10-Day Volume
1.82MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.44MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.7300USDUpdated Sep 28, 2026Other Income / Expense
11.58MUSDFY2025 · Dec 31, 202512 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
How does this company use capital?
Diagnostic
Efficiency from Aging Assets
Revenue per asset reads high, partly because those assets are largely written down.
Reads
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Diagnostic
Earnings Growth With Heavy Accrual Component
It reports a profit, with depreciation heavy in the cash bridge and receivables rising.
Reads
Depreciation Intensity
Most of its equipment is already written off, and depreciation is larger against its cash flow than its industry's.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -236.4%, lower than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: -2.36Industry median: -0.24Industry P5: -1.76Peers compared: 193
Debt-to-equity is 25.16×, higher than 95% of its Biotechnology peers (median 0.12×)Significant
Debt-to-equity: 25.16Industry median: 0.12Industry P95: 2.33Peers compared: 193
Price-to-book is 55.66×, higher than 95% of its Biotechnology peers (median 4.62×)Significant
Price-to-book: 55.66Industry median: 4.62Industry P95: 31.44Peers compared: 193
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.48Receivables vs revenue divergence: 2.56
High gross margins eroded by operating costsNotable
Gross Margin: 0.95Profit Margin: -0.07
Significant cash reserves alongside high leverageNotable
Cash (USD): 489,176,992Total Debt (USD): 616,905,024Debt-to-Equity: 25.16
Financial Health
Altman Z-Score 4.6: safe zoneNotable
Altman Z-Score: 4.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.6B, above the global median of $1.18BNotable
Market cap (USD): 5,602,878,714Global Median: 1,180,223,658.953
Revenue is $591.33M, above the global median of $548.88MNotable
Revenue (USD): 591,329,984Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Cogent Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunshine Guojian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Samsung Epis Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Xeris Biopharma Holdings, Inc.
7 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierRevenue Growing With Receivables GrowingEarnings Growth With Heavy Accrual ComponentIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedDepreciation-Heavy Reported Profit
MiMedx Group, Inc.
5 interpretationsRevenue Growing With Receivables GrowingEfficiency from Aging AssetsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated Turnover
Dunelm Group plc
5 interpretationsElevated ROE With High Debt-to-Equity and Equity MultiplierRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated Turnover